Isatuximab for the treatment of relapsed/refractory multiple myeloma

References

• Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43(6):676–681.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101–119.
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–1227.
   PubMed Web of Science ®Google Scholar
• Yang WC, Lin SF. Mechanisms of drug resistance in relapse and refractory multiple myeloma. Biomed Res Int. 2015;2015:341430.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(8):995.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520.
   PubMed Web of Science ®Google Scholar
• Paquin AR, Kumar SK, Buadi FK, et al. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer J. 2018;8(12):125.
   PubMedGoogle Scholar
• Thorsteinsdottir S, Dickman PW, Landgren O, et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica. 2018;103(9):e412–e415.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(7):719–734.
   PubMed Web of Science ®Google Scholar
• Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37(14):1228–1263.
   PubMed Web of Science ®Google Scholar
• Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Supplement4):iv52–iv61.
   PubMedGoogle Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–548.
   PubMed Web of Science ®Google Scholar
• Gay F, Engelhardt M, Terpos E, et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018;103(2):197–211.
   PubMed Web of Science ®Google Scholar
• Janssen Biotech I Darzalex® [package insert]. Horsham, PA2019.
   Google Scholar
• Janssen Biotech I Darzalex Faspro™ [package insert]. Horsham, PA2020.
   Google Scholar
• Halozyme Press Release June 4. Halozyme announces Janssen receives European marketing authorization for subcutaneous DARZALEX® utilizing halozyme’s ENHANZE® technology for the treatment of patients with multiple myeloma. 2020 [Cited 2020 Jun 5]. Available from: https://www.halozyme.com/investors/news-releases/news-release-details/2020/Halozyme-Announces-Janssen-Receives-European-Marketing-Authorization-For-Subcutaneous-DARZALEX-Utilizing-Halozymes-ENHANZE-Technology-For-The-Treatment-Of-Patients-With-Multiple-Myeloma/default.aspx
   Google Scholar
• Squibb B-M Empliciti® [package insert]. Princeton, NJ2018.
   Google Scholar
• Sanofi-Aventis USL Sarclisa®[package insert]. Bridgewater, NJ2020.
   Google Scholar
• Sanofi Press Release. European commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma. 2020. [cited 2020 Jun 2]. Available from: https://www.sanofi.com/en/media-room/press-releases/2020/2020-06-02-12-47-38
   Google Scholar
• Deaglio S, Mehta K, Malavasi F. Human CD38: A (r)evolutionary story of enzymes and receptors. Leukemia Res. 2001;25(1):1–12.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Billington R, et al. CD38/CD19: A lipid raft-dependent signaling complex in human B cells. Blood. 2007;109(12):5390–5398.
   PubMed Web of Science ®Google Scholar
• Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008;88(3):841–886.
   PubMed Web of Science ®Google Scholar
• Lee HC, Aarhus R, Levitt D. The crystal structure of cyclic ADP-ribose. Nat Struct Biol. 1994;1(3):143–144.
   PubMedGoogle Scholar
• Lee HC, Walseth TF, Bratt GT, et al. Structural determination of a cyclic metabolite of NAD+ with intracellular Ca2+-mobilizing activity. J Biol Chem. 1989;264(3):1608–1615.
   PubMed Web of Science ®Google Scholar
• Lee HC, Aarhus R. A derivative of NADP mobilizes calcium stores insensitive to inositol trisphosphate and cyclic ADP-ribose. J Biol Chem. 1995;270(5):2152–2157.
   PubMed Web of Science ®Google Scholar
• Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014;20(17):4574–4583.
   PubMed Web of Science ®Google Scholar
• Moreno L, Perez C, Zabaleta A, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019;25(10):3176–3187.
   PubMed Web of Science ®Google Scholar
• Martin TG, Corzo K, Chiron M, et al. Therapeutic opportunities with pharmacological inhibition of CD38 with Isatuximab. Cells. 2019;8:12.
   Web of Science ®Google Scholar
• Zhu C, Song Z, Wang A, et al. Isatuximab Acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells. Front Immunol. 2020;11:1771.
   PubMed Web of Science ®Google Scholar
• Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016;30(2):399–408.
   PubMed Web of Science ®Google Scholar
• van Bueren L, Jakobs JD, Kaldenkoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124(21):3474.
   Web of Science ®Google Scholar
• Horenstein AL, Chillemi A, Quarona V, et al. NAD+-metabolizing ectoenzymes in remodeling tumor-host interactions: the human myeloma model. Cells. 2015;4(3):520–537.
   PubMed Web of Science ®Google Scholar
• Feng X, Zhang L, Acharya C, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23(15):4290–4300.
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Yousef S, Shorter C, et al. In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. Leukemia. 2020;34(1):317–321.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Groen RW, Noort WA, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res. 2015;21(12):2802–2810.
   PubMed Web of Science ®Google Scholar
• van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96(2):284–290.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via FCγ receptor-mediated cross-linking. J Immunol. 2016;197(3):807–813.
   PubMed Web of Science ®Google Scholar
• Martin T, Strickland S, Glenn M, et al. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer J. 2019;9(4):41.
   PubMed Web of Science ®Google Scholar
• Ozoux ML, Gulliman H, Pascuai M, et al. A first-in-human phase I study of SAR650984, a humanized anti-CD38 antibody in patients with CD38+ hematological malignancies: preliminary PK and PD results of escalation phase. Cancer Res. 2014;74(19 Suppl):2908.
   Web of Science ®Google Scholar
• Dhillon S. Isatuximab: first approval. Drugs. 2020;80(9):905–912.
   PubMed Web of Science ®Google Scholar
• Ocio E, Otero PR, Bringhen S, et al. Preliminary results from a phase I study of isatuximab (ISA) in combination with bortezomib, lenalidomide, dexamethasone (VRd), and in patients with newly diagnosed multiple myeloma (NDMM) non-eligible for transplant. Blood. 2018;132(Suppl 1):3160.
   Google Scholar
• Dimopoulos MA, Bringhen S, Anttila P, et al. Results from a phase II study of isatuximab as a single agent and in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood. 2018;132(Supplement 1):155.
   Google Scholar
• Richter JR, Martin T, Vij R, et al. Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2016;34(15_suppl):8005.
   Web of Science ®Google Scholar
• Martin TG, Mannis GN, Chari A, et al. Phase Ib study of isatuximab and carfilzomib in relapse and refractory multiple myeloma. Blood. 2016;128(22):2111.
   PubMed Web of Science ®Google Scholar
• Sunami K, Suzuki K, Ri M, et al. Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study. Cancer Sci. 2020. Sep 25. doi: 10.1111/cas.14657.
   Web of Science ®Google Scholar
• Usmani SZ, Karanes C, Bensinger WI, et al. Isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma: final results of a phase 1b feasibility/safety study. Presented at European Hematology Association Congress (EHA 25), Virtual. 2020. e-Poster EP1009.
   Google Scholar
• Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096–2107.
   PubMed Web of Science ®Google Scholar
• Schjesvold F, Richardson P, Facon T, et al. Efficacy of isatuximab with pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: Icaria-MM subgroup analysis. Haematologica. 2020;105. DOI: 10.3324/haematol.2020.253450
   Google Scholar
• Dimopoulos MA, Leleu X, Moreau P, et al. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia. 2020 May 23. DOI: 10.1038/s41375-020-0868-z.
   Google Scholar
• Harrison SJ, Richardson PG, Alegre A, et al. Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis. Clin Lymphoma Myeloma Leuk. 2019;19(10):e33.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Attal M, Pour L, et al. ICARIA-MM study: efficacy analysis according to prior lines of treatment. Clin Lymphoma Myeloma Leuk. 2019;19(10):e245–e246.
   Web of Science ®Google Scholar
• Beksac M, Richardson PG, Unal A, et al. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma and soft-tissue plasmacytomas: ICARIA-MM subgroup analysis. Presented at European Hematology Association Congress (EHA 25), Virtual. 2020. e-Poster EP978.
   Google Scholar
• Ikeda T, Sunami K, Huang S-Y, et al. Efficacy and safety of isatuximab plus pomalidomide and dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: A subgroup analysis of ICARIA-MM study. Ann Oncol. 2019;30((suppl 9)):ix92.
   Google Scholar
• Moreau P, Dimopoulos MA, Yong K, et al. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. Future Oncol. 2020;16(2):4347–4358.
   PubMed Web of Science ®Google Scholar
• Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (IKEMA): interim analysis of a phase 3, randomized, open-label study. Presented at European Hematology Association Congress (EHA 25), Virtual. 2020. Abstract LB2603.
   Google Scholar
• Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;129(25):3294–3303.
   PubMed Web of Science ®Google Scholar
• FDA News Release April 1. FDA requests removal of all ranitidine products (zantac) from the market. 2020 [Cited 2020 Jul 31]. Available from: https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market
   Google Scholar
• Ocio EM, Bringhen S, Oliva S, et al. A phase ib study of isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone (VCDI) in patients with newly diagnosed multiple myeloma non-eligible for transplantation. Blood. 2017;130(Supplement 1):3160.
   Google Scholar
• Sarclisa® (isatuximab) registration certificate in the Russian Federation August 27 2020 [Cited 2020 Sept 10]. Available from: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c754e935-ad28-4c1d-a643-0564811a2a00&t=
   Google Scholar
• Sanofi Japan Press Release June 29. Sarclisa®100 mg/500 mg IV infusion approved for relapsed or refractory myeloma 2020 [cited 2020 Jul 23]. Available from: https://www.sanofi.co.jp/-/media/Project/One-Sanofi-Web/Websites/Asia-Pacific/Sanofi-JP/Home/press-releases/PDF/2020/200629-02.pdf?la=ja
   Google Scholar
• Barr H, Dempsey J, Waller A, et al. Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia. 2018;32(11):2495–2518.
   PubMed Web of Science ®Google Scholar
• Chari A, Arinsburg S, Jagannath S, et al. Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(1):44–51.
   PubMed Web of Science ®Google Scholar
• Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015;55(6 Pt 2):1555–1562.
   PubMed Web of Science ®Google Scholar
• Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):109.
   PubMed Web of Science ®Google Scholar